Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients with EGFR mutation-positive NSCLC.
The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007)
